Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-29

Study Completion Date

2022-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

National, prospective, multicentre, non-interventional epidemiological study, conducted among oncologists and breast surgeons in community and university hospitals, from the public sector in Algeria.

The study will collect information on the characteristics, and breast carcinomas patterns of patients whose breast cancer diagnosis was confirmed by an anatomopathologist. The study will be conducted over a representative, but not exhaustive sample of Algerian female patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

National Survey on Infiltrative Breast Cancer

NCT00696527

Infiltrative Breast Cancer

COMPLETED

Case-Control Study of Inflammatory Breast Cancer in North Africa

NCT00793390

Diabetes

COMPLETED

An Observational Study to Register the Incidence of Breast Cancer and Current Clinical Care Patterns in Kenya

NCT01484483

Breast Cancer

COMPLETED

Feasibility of Breast Cancer Risk Evaluation in Women From the General Population

NCT02997384

Breastcancer

UNKNOWN

Locoregional Recurrence of Breast Cancer

NCT05988112

Locoregional Recurrence

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of:

* Four in-hospital visits (inclusion visit, visit at 3 months, visit at 6 months, visit at 12 months). All patients presenting to their oncologists/breast surgeons during a routine visit and meeting eligibility criteria will be sequentially asked to participate to the study
* In addition to the 4 visits, a phone contact with the patients will be done by the investigator or the CRO (Clinical Research Organization, independent person) or during a routine visit to the investigator, to check the patients' survival every 6 months during 5 years (8 contacts).

Duration of patient recruitment: 6 months from the date of first patient's inclusion.

Duration of patient follow-up: 60 months 3.2 Data Source A comprehensive list of all Algeria hospitals will be used as a data source in the site selection process. The list will be obtained either from the health authority, local scientific societies or professional associations, depending on the local availability of this type of information. All efforts will be made to approach and select sites/physicians.

The oncologist/breast surgeons (investigator) or one of his/her authorised representative in each participating site will complete a CRF (Case Report Form). All data to be collected will be based on the patient's medical file.

The patient will also complete an auto-questionnaire about quality of life at inclusion, 6 and 12 months follow-up.

The CRF will collect all data required for the study and will be transmitted to the project team for analysis following each eligible patient's visit to the investigator.

Data collection should be precise and reliable. The study monitor will verify the authenticity of the data, by matching the CRF with the source documents at the site, and in compliance with the guidelines for good pharmacoepidemiology practices and the recommendations of the Association of French-speaking Epidemiologists (ADELF).

In total, 10 to 15% of the eCRFs (electronic Case Report Form) by site will be verified.

Following the data verification, lists of non-conformity will be generated and transmitted to the study investigators.

The investigator should provide the Sponsor, when requested, all necessary and important data for control. The access to the complete patient's medical file, should be authorised by the investigator, providing that the patient's confidentiality is preserved.

Patients who do not give their written informed consent will only be listed, their data will not be collected on the patient form by the Sponsor.

In case of any particular problem, an audit request can be made.

This study will include representative centres of breast cancer managing departments in each sanitary region defined by the Ministry of health, the investigational centres will propose to all patients whom met eligibility criteria to participate to the study. 1500 patients are expected to be enrolled in the study (incidence study).

Study duration: 66 months

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oncology Epidemiology Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Breast Cancer Patients

Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy

NIS (Non Interventional Study) observational study

Intervention Type OTHER

NIS observational study : Epidemiologic registry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NIS (Non Interventional Study) observational study

NIS observational study : Epidemiologic registry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients will be eligible to participate to the study if they fulfil all of the following criteria:

* Female patients
* Aged 18 years and over
* Newly diagnosed with breast cancer all stages confirmed during the study period by an anatomopathologist, defined as a first diagnosis of breast cancer based on anatomopathological results from at least a microbiopsy
* Provision of subject informed consent.

Exclusion Criteria

Patients will not be eligible to participate if any of the following criteria are present:

* Informed consent not obtained.
* Patients with a mental or psychological disorder according to their treating clinicians
* Patients participating in an interventional study or already included in the study. A patient could be consulted and treated in two different centres, thus a codification system will be generated to avoid duplicate participation

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No